Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Rheumatology
•
Osteoporosis
Is there any concern with starting romosozumab in a patient who is taking raloxifene for a history of breast cancer?
Related Questions
How long after parathyroidectomy (for parathyroid adenoma with hyperparathyroidism) do you wait before initiating romosuzumab in an older patient with osteoporosis and very high fracture risk?
Would you use romosozumab in a patient with a cardiovascular event more than 2 years prior?
Would you continue zolendronic acid infusions if the bone density decreases significantly in year two?
How do you approach significant change in BMD in premenopausal patient on tamoxifen?
Is there a PTH elevation above which you would be hesitant to use an anabolic agent in a patient with osteoporosis and CKD stage 4 or 5?
How do you approach a patient with elevated bone specific ALP (>2X the normal limit), but no other evidence of Paget's disease?
Have the results of the ancillary study of the VITAL trial, demonstrating that Vitamin D3 supplementation did not reduce the incident rate of fractures in generally healthy midlife and older adults, changed how you prescribe Vitamin D?
Is it safe to give an anabolic agent for osteoporosis without following up with an anti-resorptive agent?
What is your approach to the management of isolated total hip osteoporosis in a post menopausal woman without fracture history and low FRAX risk (based on their femoral neck osteopenic t score)?
Given the risk of hypocalcemia in dialysis dependent patients treated with denosumab, what is the best method of treatment for osteoporosis for these patients, and should we be transitioning to a different agent?
